Sana Biotechnology (NASDAQ:SANA) Stock Rating Lowered by Wall Street Zen

Sana Biotechnology (NASDAQ:SANA) was downgraded by investment analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a research note issued to investors on Monday.

Other research analysts also recently issued reports about the company. Weiss Ratings downgraded Sana Biotechnology from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Friday, May 1st. Wedbush upped their price objective on Sana Biotechnology from $6.00 to $7.00 and gave the stock an “outperform” rating in a research note on Tuesday, April 14th. Finally, Rodman & Renshaw began coverage on Sana Biotechnology in a report on Monday, May 11th. They issued a “buy” rating and a $16.00 price objective for the company. Seven research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, Sana Biotechnology presently has a consensus rating of “Moderate Buy” and an average price target of $9.50.

Sana Biotechnology Price Performance

Shares of NASDAQ:SANA opened at $3.16 on Monday. The company’s 50-day moving average price is $3.26 and its two-hundred day moving average price is $3.59. Sana Biotechnology has a one year low of $2.61 and a one year high of $6.55. The stock has a market capitalization of $879.40 million, a PE ratio of -3.40 and a beta of 2.13.

Sana Biotechnology (NASDAQ:SANA) last announced its quarterly earnings data on Monday, May 11th. The company reported ($0.14) earnings per share for the quarter, beating the consensus estimate of ($0.15) by $0.01. On average, analysts anticipate that Sana Biotechnology will post -0.59 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Bank of America Corp DE boosted its holdings in shares of Sana Biotechnology by 148.4% during the first quarter. Bank of America Corp DE now owns 2,946,861 shares of the company’s stock worth $8,487,000 after acquiring an additional 1,760,610 shares during the period. Royal Bank of Canada increased its stake in shares of Sana Biotechnology by 76.8% during the first quarter. Royal Bank of Canada now owns 12,285 shares of the company’s stock worth $35,000 after purchasing an additional 5,338 shares during the period. Cetera Investment Advisers lifted its holdings in Sana Biotechnology by 50.2% during the 1st quarter. Cetera Investment Advisers now owns 26,181 shares of the company’s stock worth $75,000 after purchasing an additional 8,750 shares during the last quarter. Dimensional Fund Advisors LP lifted its holdings in Sana Biotechnology by 118.9% during the 1st quarter. Dimensional Fund Advisors LP now owns 291,268 shares of the company’s stock worth $839,000 after purchasing an additional 158,190 shares during the last quarter. Finally, Swiss National Bank boosted its stake in Sana Biotechnology by 2.0% in the 1st quarter. Swiss National Bank now owns 342,600 shares of the company’s stock valued at $987,000 after purchasing an additional 6,800 shares during the period. Institutional investors and hedge funds own 88.23% of the company’s stock.

Sana Biotechnology Company Profile

Sana Biotechnology is a clinical-stage biopharmaceutical company focused on the development of engineered cells as medicines with the goal of treating a broad range of diseases. The company applies advanced gene editing and gene delivery technologies to create next-generation cell therapy products for oncology, genetic disorders and other serious diseases. By leveraging both ex vivo and in vivo approaches, Sana aims to repair or replace damaged cells and restore healthy tissue function.

The company’s core platform integrates proprietary gene writing capabilities alongside established gene editing tools such as CRISPR–Cas9.